I

nvestorsand the media

Company News

Home > Investors & media > Company News

Welcome to 2023 DCAT Week

Source: Sinopep Preparations     Time: [2023-03-20]

Sinopep-Allsino Biopharmaceutical Co., Ltd will participate in the 2023 DCAT Week (Annual Meeting of the Association for the Joint Trade of Pharmaceuticals and Chemicals) in New York, USA on March 20-23 (local time). We sincerely invite all industry experts and partners to the DCAT conference in New York for meeting!

01.Conference Information

Conference Name: DCAT Week (Annual Meeting of the Association of Allied Pharmaceutical and Chemical Traders)

Conference Date: 2023.3.20-2023.3.23

Email: info@sinopep.com

Address: Club Quarters Hotel, Grand Central 128 East 45th Street, Room 908

02.About DCAT WEEK

DCAT Week is the premier global event held annually in New York City for companies engaged in the Bio/Pharmaceutical Manufacturing Value Chain. It is hosted by the Drug, Chemical & Associated Technologies Association (DCAT), a not-for-profit, member-supported, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies.

03.About Sinopep-Allsino Biopharmaceutical Co., Ltd

Sinopep-Allsino Biopharmaceutial Co., Ltd. is a leading, technology driven company specialized in developing and manufacturing Peptides, Oligonucleotides and small molecules intermediates, APls and drug products. With about 15 years of diverse and extensive experience, we have provided high quality products and services to multinational pharmaceutical corporations and biotechnology companies around the world from preclinical to commercial stages. Sinopep-Allsino currently has three R&D centers supporting manufacturing projects across two manufacturing sites, which met high global quality and EHS standards, and are approved by US FDA and EDQM.

Mobile version

Contact

Sales Department:
+86-571-88671216 (FDF)
+86-571-88672696 (API and intermediates)